Johnson & Johnson Hit With $8 Billion Jury Verdict in Risperdal Suit
A Philadelphia jury found that a subsidiary downplayed the risks that the anti-psychotic drug could lead to breast growth in boys.
View original article
Contributor:
A Philadelphia jury found that a subsidiary downplayed the risks that the anti-psychotic drug could lead to breast growth in boys.
View original article
Contributor: